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Atypical antipsychotics in the treatment of schizophrenia
Abstract
Over the last few years atypical antipsychotics have been used increasingly in the
pharmacological treatment of schizophrenia. This review provides an overview of the
pharmacological and clinical characteristics of atypical antipsychotics. In particular we discuss
their efficacy in treating psychotic and negative symptoms as well as treatment-refractory
patients. The most important side effects as well as their possible interactions are reviewed in
detail. Recommendations for the clinical use are given.
Atypical antipsychotics
in the treatment of schizophrenia
René Bridler, Daniel Umbricht
Psychiatric University Hospital Zurich
There is overwhelming evidence that antipsy-
chotics are superior to placebo in the acute and
long-term treatment of schizophrenia [1]. In com-
parison to patients who continue to receive an-
tipsychotic treatment after an acute episode, pa-
tients on placebo treatment relapse significantly
more often, have to be rehospitalised more fre-
quently and demonstrate more psychotic symp-
toms upon readmission. Prophylactic treatment
with a standard or slightly reduced dose provides
the best protection against relapse. Low dose
strategies (1/10 of the standard dose) are associated
with unacceptably high relapse rates of up to 60%
[2]. The so-called targeted or interval treatment
(tapering of the antipsychotic once the clinical sit-
uation has stabilised, recommencing of treatment
when prodromal symptoms appear) are also asso-
ciated with an increased risk of relapse and cannot
be recommended for the majority of patients. In
addition, there is evidence that this kind of treat-
ment may be associated with an increased inci-
dence of tardive dyskinesia [3]. In general, depot
medication is not superior to oral administration
with regard to various outcome criteria [4–6].
However, patients with a history of poor compli-
ance seem to benefit most from this route of ad-
ministration [7]. In general, any antipsychotic with
proven effectiveness in the acute treatment phase
can be used in long-term treatment as relapse pre-
vention. After withdrawal of antipsychotics relapse
may occur even after several years of full remission
in up to 75% of all cases [8, 9]. Treatment with an-
tipsychotics has been demonstrated to reduce rates
of relapses and rehospitalisations in a substantial
number of patients over periods of many years. For
this reason antipsychotics have to be considered an
effective and inexpensive treatment of schizophre-
nia [10]. 
Over the last few years atypical antipsychotics
have been used increasingly in the pharmacologi-
cal treatment of schizophrenia. This review pro-
vides an overview of the pharmacological and clin-
ical characteristics of atypical antipsychotics. In
particular we discuss their efficacy in treating psy-
chotic and negative symptoms as well as treat-
ment-refractory patients. The most important side
effects as well as their possible interactions are re-
viewed in detail. Recommendations for the clini-
cal use are given. 
Key words: atypical antipsychotics; schizophrenia;
treatment; side effects
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Introduction
Problems of long-term treatment
In long-term treatment studies of schizophre-
nia up to one third of all patients become non-
compliant with treatment during the first year [11].
There are multiple reasons for this noncompli-
ance. Some patients may refuse treatment due to
poor insight, some patients as a result of psychotic
symptoms themselves [12]. There may also be fac-
tors in the environment of the patient that con-
tribute to noncompliance. For instance, in a rep-
resentative survey in Germany only 20% of the in-
terviewees recommended antipsychotics as a treat-
ment of schizophrenia, 40% each advised against
it or took an undecided view [13]. In addition, care-
givers themselves may contribute to noncompli-
ance by poorly following internationally accepted
guidelines for the pharmacological treatment of
schizophrenia [14]. In other cases there may be un-
desired side effects, such as akathisia, dystonia,
parkinsonism, tardive dyskinesia, and the conse-
quences of an increased prolactin level all of which
may limit long-term treatment with antipsy-
chotics. Also, not all patients derive a full benefit
from treatment with neuroleptics. A substantial
number of patients will relapse despite adequate
antipsychotic treatment or develop partial or full
resistance to treatment with antipsychotics. Fi-
nally, it is important to consider that antipsychotics
primarily reduce positive symptoms, whereas so-
called negative symptoms are ameliorated only to
a moderate degree or may even be exacerbated
[15].
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Atypical antipsychotics
The observation that effective antipsychotic
treatment with classical antipsychotics was associ-
ated with extrapyramidal side effects (EPS) led to
the belief that only compounds that also produced
these side effects were therapeutically effective.
However, the introduction of clozapine in 1973 re-
sulted in a revision of this hypothesis since this
drug showed excellent antipsychotic efficacy in the
absence of extrapyramidal side effects [16]. Unfor-
tunately, the propensity of clozapine to cause
agranulocytosis led to its withdrawal in many
countries or to restrictions in its use [17]. In the
late 1980’s a pivotal multicenter study demon-
strated the superiority of clozapine over classical
antipsychotics in treatment-refractory schizo-
phrenic patients [18]. This caused a resurgence of
interest in this compound. Attempts to develop
clozapine-like antipsychotics that lack its risk of
agranulocytosis led to the introduction of new sub-
stances for the treatment of schizophrenia. These
include risperidone, olanzapine, quetiapine,
ziprasidone, and amisulpride. Sertindole, on the
market for only a short period, was suspended in
1999 after ventricular arrhythmias due to a pro-
longed QTc-interval had been associated with this
drug.
Despite the heterogeneity of their pharmaco-
logical and physiological characteristics all new an-
tipsychotics, together with clozapine, are called
atypical neuroleptics or antipsychotics (other
terms that have been used to refer to these an-
tipsychotics include “second-generation” and
“novel” antipsychotics; throughout this paper we
will use the term “atypical antipsychotics”). In the
last few years positron emission tomography
(PET) studies have provided important informa-
tion about their mechanisms of action. Most atyp-
ical antipsychotics have been shown to demon-
strate a strong affinity for serotonin 5-HT2 re-
ceptors, but relatively weak affinity for the
dopamine D2 receptor (see also below). In addi-
tion, they demonstrate a selectivity for mesolimbic
over nigro-striatal regions in their effects on the
dopamine system [19–28]. These features are as-
sumed to represent important common character-
istics of atypical antipsychotics and to be responsi-
ble for their reduced propensity to cause EPS. This
feature is often given as the main characteristic
defining atypicality. Table 1 highlights some im-
portant pharmacological and clinical characteris-
tics of atypical antipsychotics (individual features
may vary for different substances). For an excellent
review of atypical antipsychotics that focuses on
each drug individually the interested reader is re-
ferred to a recent publication by the Task Force of
the World Psychiatric Association [29].
Lower affinity for D2 receptors (except amisulpride)
Higher affinity for 5-HT2 receptors (except amisulpride)
Effective against positive symptoms
Questionably effective against negative symptoms
Lower propensity to cause EPS
Lower propensity to cause TD
Lower prolactin increase (except amisulpride and risperidone)
Table 1
Pharmacological and
clinical features of
atypical antipsy-
chotics.
Efficacy of atypical antipsychotics
Positive symptoms
Positive symptoms comprise hallucinations,
delusions, thought disorders, thought insertion or
withdrawal as well as some psychomotor abnor-
malities. In controlled studies atypical antipsy-
chotics have demonstrated comparable or even
slightly better global clinical efficacy in the acute
treatment of schizophrenia compared to haloperi-
dol, while they perform significantly better than
placebo in reducing positive symptoms [30–32].
These findings hold true for first-episode as well
as chronic, multi-episode patients. With regard to
long-term maintenance treatment all atypicals
have demonstrated a positive effect on relapse pre-
vention in controlled trials (the only exception is
quetiapine for which no controlled maintenance
treatment trials have been conducted). For these
reasons atypical antipsychotics are recommended
as first line treatment in all phases of schizophre-
nia [33, 34].
Negative symptoms
The term negative symptoms refers to clinical
features such as flat affect, emotional withdrawal,
poverty of speech and thought, lack of drive and
motivation, anhedonia, disinterest, and social
withdrawal. Negative symptoms are not specific to
schizophrenia and have to be differentiated pri-
marily from symptoms of depression. In the as-
sessment of negative symptoms the differentiation
between primary and secondary negative symp-
toms has become customary [35, 36]. Primary neg-
ative symptoms are considered those that are gen-
uine or intrinsic to the disorder, thus long-lasting
and stable over time with little variation; a hy-
podopaminergic state of the meso-cortical
dopamine system resulting in prefrontal hy-
podopaminergia has been implicated in primary
negative symptoms [37]. Secondary negative symp-
toms may present similarly, but are thought to re-
sult from positive psychotic symptoms, side effects
due to antipsychotic medication (parkinsonism),
depressive symptoms, and social understimulation.
Thus, they tend to fluctuate and should only last as
long as the underlying cause is present [38].
Initial encouraging results with clozapine [18]
raised the hope that atypical antipsychotics would
offer a better treatment for negative symptoms
than typical agents which are considered ineffec-
tive by most clinicians. However, Leucht et al.
demonstrated in a meta-analysis that even classical
antipsychotics are superior to placebo in reducing
negative symptoms [31]. These authors found that
in studies that investigated effects on negative
symptoms and used haloperidol as the comparator
drug only risperidone and olanzapine proved to be
superior in their effects on negative symptoms,
while quetiapine did not show any advantage.
Since these studies did not differentiate between
primary and secondary negative symptoms no con-
clusions can be drawn about the effects of these
drugs on primary negative symptoms. For these
reasons attempts have been made to use path
analyses to demonstrate effects on primary nega-
tive symptoms. In these models the effects of pos-
itive and depressive symptoms as well as ex-
trapyramidal side effects on negative symptoms are
statistically taken into account and the remaining
“true” negative symptom level is used to evaluate
the effect of the drug in question [39, 40]. The
power of this method, however, is reduced by the
fact that other factors such as social understimula-
tion, anxiety etc. are not considered in the model.
In addition, the original design of the study was not
intended to address the potential effect of the in-
vestigational drug on primary negative symptoms.
Two recently published studies on treatment ef-
fects on negative symptoms that differentiated be-
tween primary and secondary negative symptoms
could not demonstrate any significant effects on
primary negative symptoms for clozapine or olan-
zapine [41, 42].
However, a true ameliorative effect on primary
negative symptoms may be shown by the substi-
tuted benzamide amisulpride [43–45]. Amisul-
pride demonstrates mesolimbic selectivity and is a
pure D2/D3 antagonist possessing affinity for both
pre- and postsynaptic receptors. The exact role of
its D3 antagonism is not known, however. At low
doses the blockade of presynaptic receptors seems
to prevail. This results in increased dopamine re-
lease into the synaptic cleft and thus in an activat-
ing, pro-hedonistic effect. At higher doses (>400
mg/d) the postsynaptic antagonism starts to dom-
inate and leads to classical neuroleptic effects. Four
controlled studies in patients with primary nega-
tive symptoms using doses of amisulpride between
50 and 300 mg/d demonstrated a significantly
greater decrease of negative symptoms after 6 to
26 weeks of treatment in the active treatment
group than in the placebo group [43–46]. It is im-
portant to note that this improvement took place
independently of any changes in depressive and
psychotic symptoms or extrapyramidal side effects.
In addition, no increase of positive symptoms was
observed. A fifth double-blind study in elderly
long-term inpatients manifesting moderate to se-
vere negative symptoms compared amisulpride to
haloperidol with both drugs given in systematically
reduced dosing strategy [47]. In 18% of the amisul-
pride group and 27% of the haloperidol group an
increase of positive symptoms necessitated a dose
increase. The remainder of the patients remained
stable. Negative symptoms changed little over the
course of the study. Still, comparison of the drug
effects demonstrated a clear, albeit not statistically
significant trend in favour of amisulpride in re-
ducing flat affect and apathy [47]. (The interested
reader is referred to a recently published meta-
analysis of amisulpride trials by Leucht et al. [32]).
Ziprasidone, a novel antipsychotic with a
unique receptor binding profile, could possibly
turn out to be effective against primary negative
symptoms as well. Besides its high affinity for D2
receptors and antagonistic properties at various 5-
HT receptors it also demonstrates presynaptic re-
uptake-inhibition of serotonin and norepineph-
rine comparable to antidepressants [48]. The sero-
tonin reuptake inhibition properties of ziprasidone
may be important in its effects on negative symp-
toms since fluvoxamine, a SSRI, has been reported
to reduce such symptoms in schizophrenia [49].
Indeed, in a 1-year controlled trial in patients with
chronic stable schizophrenia with only moderate
levels of positive symptoms but high levels of neg-
ative symptoms ziprasidone was associated with a
small, but statistically significant improvement in
negative symptoms compared to placebo [50].
Even more interesting, in a head-to-head compar-
ative controlled trial over 3 months in schizo-
phrenic patients with predominant negative symp-
toms ziprasidone (40–80 mg) and amisulpride
(50–100 mg) demonstrated comparable efficacy in
improving negative symptoms [51]. Consistently,
in a 28-week comparison of ziprasidone and
haloperidol in stable schizophrenic outpatients
significantly more patients treated with ziprasi-
done demonstrated a reduction of negative symp-
toms of 20% or more than patients treated with
haloperidol [52].
Treatment-refractory patients
Although there is no universally accepted def-
inition of treatment refractoriness a partial or full
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resistance to treatment is customarily assumed if a
patient fails to adequately respond, ie, show re-
duction of his/her positive symptoms, to at least
two antipsychotics belonging to a different chem-
ical class given in sufficiently high doses of 6–8
weeks. An insufficient or complete lack of response
to antipsychotic treatment has to be expected in up
to 30% of chronic patients – a number which high-
lights the importance of this problem for the
everyday care of these patients [16]. In 1988 Kane
et al. published the results of a carefully designed
study in which the superiority of clozapine over
chlorpromazine in the treatment of severely ill,
treatment resistant inpatients was investigated
[18]. The inclusion criteria were very strict and in-
cluded a documented history of three previous tri-
als of different neuroleptics to which the patient
did not show a response, a five year history of con-
sistently low functioning and, in addition, a failure
to respond to a prospective 6-week open trial of
haloperidol. 268 patients fulfilled these criteria
and were randomised to a 6 week double-blind
treatment with clozapine or chlorpromazine.
Analyses included all patients who had at least one
symptom rating (1 week) after enrollment in the
study. 88% in the clozapine group and 87% in the
chlorpromazine group finished the study. 30% of
the patients in the clozapine group met the a pri-
ori response criteria, whereas only 4% in the chlor-
promazine group did so (p <0.001; NNT = 4). Later
studies confirmed these findings in less ill patient
populations [53, 54]. Thus, the superiority of
clozapine over conventional antipsychotics in the
treatment of treatment refractory patients with
schizophrenia is well established [30, 55].
Clozapine is the only atypical antipsychotic for
which therapeutic serum levels have been estab-
lished [56, 57]. Several studies have demonstrated
a significantly higher response rate in patients with
a serum clozapine level above 250 ng/ml (when
clozapine is given twice daily) [56]. In patients who
do not respond to adequate doses of clozapine
(300–600 mg/d) determination of serum levels are
recommended since up to 40-fold differences in
serum level between patients treated with the same
dose of clozapine have been described [57]. Simi-
larly, in patients who exhibit high levels of side ef-
fects at low doses of clozapine, determination of
serum levels may be informative. In addition, op-
timal therapeutic serum levels may also exist for
olanzapine: The optimal range of olanzapine
serum levels seems to be 20 to 40 ng/ml, concen-
trations of 80 ng/ml are associated with more ex-
trapyramidal side effects [58].
The observation that most atypical antipsy-
chotics share some pharmacological and clinical
characteristics of clozapine has led to the assump-
tion and expectation that they should also show su-
periority over classical neuroleptics in the treat-
ment of refractory patients. A few studies seem to
support this view [59–63]. However, some aspects
of these studies restrict the inferences that can be
safely drawn from their results. For instance, some
studies used an open treatment design, in others
the definition of treatment resistance was less
strict; some studies also included other diagnostic
groups (eg, schizophreniform or schizoaffective
disorder). For instance, Bondolfi et al. [61] found
response rates of 65% and 67%, respectively, in a
study comparing clozapine and risperidone in 86
hospitalised patients with chronic treatment-re-
fractory schizophrenia. These surprisingly high
response rates are likely explained by the less strin-
gent definitions of treatment resistance used in this
study. In addition, patients were enrolled into the
study whose lack of response was due to intoler-
ance rather than true treatment resistance. In an-
other controlled study with more stringent inclu-
sion criteria concerning treatment resistance
risperidone was associated with a more rapid onset
of effects compared to haloperidol after four weeks
[64]. However, this significant advantage in the re-
duction of psychotic symptoms disappeared after
another four weeks. At the end of the two months
study risperidone did not show any superiority
over haloperidol anymore. Of particular interest is
an eight week study conducted by Conley at al.
[65]. This study used the almost identical study de-
sign of the seminal study by Kane et al. [18] and
compared olanzapine to chlorpromazine. Treat-
ment with neither drug was associated with a sig-
nificant reduction of psychotic symptoms in these
treatment refractory patients. Interestingly, the
patients in this study who failed to respond to olan-
zapine were offered to enter an 8 week open-label
treatment study with clozapine. Of the 27 patients
who entered this study 11 (41%) showed a clinical
response [66]. Finally, an 8 week study of quetia-
pine failed to show any superiority over haloperi-
dol in the treatment of patients with a history of
partial non-response to treatment with a conven-
tional antipsychotic (fluphenazine) [67]. To our
knowledge no data on the effects of amisulpride
and ziprasidone in treatment-refractory patients
are available at this time. In summary, superiority
over conventional antipsychotics in the treatment
of treatment-refractory patients has only been
shown unequivocally for clozapine. Table 2 pro-
vides information about the recommended daily
doses for the atypical antipsychotics discussed.
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Risperidone 2–8 mg
Olanzapine 5–20 mg
Quetiapine 150–750 mg
Ziprasidone 80–160 mg
Amisulpride 50–300 mg3, 5
400–800 mg4, 5
Clozapine 200–600 mg
1 individual cases, particularly first episode patients and elderly 
patients, may require lower doses
2 doses amongst the compounds are not necessarily equivalent
3 in patients with predominantly or purely negative symptoms
4 in patients with positive symptoms, start with 400 mg/d
5 in patients with impaired renal function the dose has to be 
adjusted
Table 2
Commonly used
daily doses of 
atypical antipsy-
chotics [29].1, 2
Neurocognitive deficits
Significant neurocognitive deficits are major
and enduring features of the clinical phenotype of
schizophrenia [68–71], and they impair a broad
array of cognitive domains – ranging from classi-
cal neuropsychological deficits to altered informa-
tion processing [72–82]. In recent years the evi-
dence has been accumulating that they constitute
a major limiting factor for rehabilitation and func-
tional outcome [68, 72, 83]. 
Classical antipsychotic drugs improve these
deficits only modestly at best [68, 72, 84, 85]. With
the growing realisation that neurocognitive
deficits constitute an important factor for the func-
tional outcome the effects of atypical antipsy-
chotics on cognitive deficits have been increasingly
investigated. Based on the results of mostly open-
label studies claims of their superiority over classi-
cal antipsychotics in this regard have been made
[86, 87]. However, in a recent review of this liter-
ature and the methodology of the studies Harvey
and Keefe [88] have pointed to several important
factors limiting the conclusions that can be drawn
from this literature: a) of a total of 20 studies re-
viewed only 5 employed a double-blind random as-
signment design and of these only 2 studies lasted
more than 9 weeks whilst only one lasted more
than 26 weeks; b) doses of typical antipsychotics
that patients were treated with prior to being
switched to atypical antipsychotics or that were
used as comparator treatment were reported in
only about half of the trials. When reported these
doses were – based on modern standards – exces-
sively high, ie, ranging from 736 to 924 mg chlor-
promazine equivalents corresponding to about 14
to 18 mg of haloperidol. Thus, most studies were
biased in favour of the atypical drug – due to the
unblinded design and the unfavourable dosage of
the typical agents at baseline or during the trial.
Thus, many reported positive effects of atypical
antipsychotics on cognition may be due to coming
off an excessively high dose of typical antipsy-
chotics. A recent study by Green et al. highlights
this issue [89]. This research group had previously
reported a significant improvement of verbal
memory during treatment with risperidone in
comparison with haloperidol given at 15 mg/d
[90]. In their most recent study they compared the
effects of low-dose haloperidol (mean 5 mg/d) to
risperidone on cognitive deficit in a 2 year double-
blind study [89]. Interestingly, they did not find
any significant differences between the two treat-
ments. Indeed, patients on haloperidol showed a
more rapid initial improvement on the global
measure of cognition than patients treated with
risperidone. Two more recent reports on double-
blind random assignment studies compared effects
of haloperidol, clozapine, olanzapine, and risperi-
done on measures of cognition in long-tem stud-
ies [91, 92]. In the study by Purdon et al. [92] treat-
ment with olanzapine was associated with signifi-
cantly greater improvement of an index of general
cognitive functioning compared to haloperidol
and risperidone, whereas no difference was ob-
served between treatment with haloperidol and
risperidone. In contrast, in the study by Bilder et
al. [91] both olanzapine and risperidone treatment
were associated with significantly greater im-
provement of global neurocognitive functioning
than treatment with haloperidol after 14 weeks.
More detailed analyses demonstrated that the ef-
fects of the atypical antipsychotics investigated dif-
fered in the profile of their effects on different cog-
nitive domains: While treatment with olanzapine
led to improvement in the general and attentional
domain, risperidone treatment was associated with
significant improvement of memory functions. In
addition, defining clinically significant improve-
ment on global neurocognitive functioning as a
change of at least 0.5 standard deviations the au-
thors found that about 24% of patients treated
with haloperidol, about 33% of patients treated
with clozapine, about 57% of patients treated with
risperidone and about 76% of patients treated with
olanzapine showed clinically significant improve-
ment – a highly significant difference. While these
methodologically rigorous studies support the hy-
pothesis of an ameliorative effect of atypical an-
tipsychotics on cognition, caution is warranted: In
the study be Purdon et al. a high drop-out rate was
observed, particularly in the haloperidol group,
making interpretation of the results difficult. In the
study by Bilder et al. the mean doses prescribed
were haloperidol 26.8 mg, risperidone 11.3 mg,
olanzapine 30 mg and clozapine 498 mg. Thus,
given the recent findings by Green et al., 2002,
cited before, it could be argued that this study was
biased against any positive findings in the haloperi-
dol group. While true effects of atypical antipsy-
chotics may indeed exist, the current evidence ar-
gues against an overly optimistic view until more
studies using appropriate dosing of the compara-
tor drug and employing randomised, double-blind
designs have been completed. Nevertheless, given
the lack of true pharmacological enhancers of cog-
nition, atypical antipsychotics may represent the
“best of all bad treatments” in clinical practice for
patients with substantial cognitive deficits. 
Affective symptoms and suicidality
Affective, mostly depressive symptoms, are a
commonly encountered problem in the treatment
of schizophrenia [93]. These may be associated
with psychotic symptoms [94], but also stem from
demoralisation, and from the occurrence of true
major depression or the presence of a schizoaffec-
tive disorder. In general, if a patient presents with
signs and symptoms of a major depression that do
not remit with successful antipsychotic treatment
a trial of an antidepressant drug should be initiated.
However, if a patient refuses such treatment or if
enduring subsyndromal affective symptoms are
present, treatment with an atypical antipsychotic
may offer antidepressant effects not observed dur-
ing treatment with typical agents [95]. The evi-
dence for this stems mainly from studies in patients
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with schizoaffective disorder and from studies on
the antipsychotic efficacy of atypical drugs in
which depressive signs and symptoms were as-
sessed as well. For a more detailed review of this
topic we would like to refer the interested reader
to a recently published review on this subject [95].
Suicidality represents an additional important
clinical problem that unfortunately is encountered
far too often in schizophrenic patients. Actual sui-
cide attempts do not only depend on the presence
of suicidality, but also on the degree of impulsive-
ness in a given patient – a symptom which, ac-
cording to some evidence, may improve during
treatment with atypical antipsychotics. Interest-
ingly, clozapine may offer unique benefits in the
treatment of suicidal patients. Meltzer et al. [96]
reported on the effects of clozapine on suicidality
and suicide attempts in 88 patients. These authors
found a significant decrease in suicidality and in
the number of suicide attempts in these patients
after 6 months of treatment with clozapine com-
pared to the period prior to clozapine treatment.
These changes were associated with improvement
of depression and hopelessness as well. These en-
couraging results were recently tested in a double-
blind, random assignment, prospective study that
specifically assessed the effects of clozapine and
olanzapine on suicidality and suicide risk over two
years [97]. A total of 980 patients were enrolled in
this international, multicentre study. Clozapine
significantly reduced both suicidality and suicide
risk compared to olanzapine. It lowered the haz-
ard ratio for suicide attempts significantly. Ex-
pressed differently, patients on clozapine had 24%
less risk of suicide attempts or hospitalisation due
to imminent suicide risk than patients on olanza-
pine. Thus, given the current level of evidence
clozapine should be recommended as first-line
treatment in patients with schizophrenia and
schizoaffective disorder who are at high risk of sui-
cidality.
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Side effects of atypical antipsychotics
Atypical antipsychotics show a host of unto-
ward effects. They can, at least partly, be under-
stood as the result of specific antagonist action at
central or peripheral receptors. In the following
paragraphs the most important side effects will be
discussed. For a more comprehensive discussion of
all side effects interested readers are referred to the
literature. 
Acute extrapyramidal side effects (EPS)
Acute extrapyramidal side effects result when
at least 75–80% of the D2 receptors in the basal
ganglia are blocked by antipsychotics [23]. They
are manifested clinically as parkinsonism, akathisia
(subjective and objective restlessness) or as acute
dystonia (muscle cramps in the face and neck). In
contrast, particularly to high potency antipsy-
chotics such as haloperidol that show strong and
unselective affinity to the D2 receptors in the
CNS, atypical antipsychotics in general cause less
EPS. Therefore, their use results in a significantly
lower treatment with anticholinergic medication.
The available evidence indicates that clozapine and
quetiapine show the most favourable EPS profile;
only in very rare cases do they cause dysfunction
of the extrapyramidal motor system. This is con-
sistent with the results of several PET studies in
which for both substances a subtotal blockade of
5-HT2 receptors at any dose level has been
demonstrated. However, even at the highest doses
D2 receptor blockade never exceeded a moderate
level (about 65%) and thus remained below the
threshold for the occurrence of EPS (75–80%) [21,
24, 98–100]. In contrast, the D2 receptor blockade
of risperidone and olanzapine increases continu-
ously with escalating doses resulting ultimately in
EPS [21]. The threshold levels of D2 receptor
blockade for the occurrence of EPS appear to be
reached with a dose of risperidone of 4–5 mg/d and
of olanzapine of about 20–25 mg/d [21]. When ex-
ceeding these doses a successive loss of atypical fea-
tures and a significant increase in EPS has to be ex-
pected. Indeed, cases of serious akathisia have been
described for olanzapine [21, 22, 101–104]. Simi-
larly, amisulpride seems to loose its mesolimbic se-
lectivity and to cause EPS more often when daily
doses over 800–1000 mg are given [25]. Ziprasi-
done has demonstrated clear advantages over
haloperidol in long term studies with respect to
acute EPS [52]. 
However, individual sensitivity, rates of ab-
sorption and metabolism as well as interactions
with other medications result in a substantial het-
erogeneity so as to make clear predictions con-
cerning tolerance difficult.
Tardive dyskinesia (TD)
Tardive dyskinesias are those hyperkinesias
that are associated with prolonged treatment with
antipsychotics and manifest clinically as repetitive,
involuntary, rather fast movements (smacking,
blinking, grimacing, toe and finger movements),
or, more rarely, as dystonic movements in various
muscle groups. In contrast to acute EPS, TDs
mainly emerge after a prolonged treatment with
conventional antipsychotics (months to years).
They are believed to be related to permanent or
repeated blockade of the D2 receptors in the basal
ganglia by antipsychotics. Known risk factors in-
clude higher age, affective disorders, female sex,
exceeding a given cumulative neuroleptic dosage,
as well as preexisting diseases of the CNS
[104–106]. The emergence of acute EPS is a sig-
nificant predictor for the occurrence of TD later
on [105, 107, 108]. Although the occurrence of se-
vere TD is rather rare even mild forms can lead to
social stigmatisation and reduce the compliance
and acceptance of treatment. About 20–30% of all
patients treated with conventional antipsychotics
develop TD [105–107, 109, 110]. During the first
few years of treatment the cumulative yearly inci-
dence of de novo TD is about 5% in adult patients
[111]. In elderly patients the corresponding inci-
dence is upto 6 times higher [107, 108]. The avail-
able evidence indicates that among the newer atyp-
ical antipsychotics risperidone, olanzapine,
ziprasidone, and probably also quetiapine cause
less TD than classical antipsychotics [50,
112–114]. It is unclear at this point if this also holds
true for amisulpride. However, an advantage, ob-
served in an open long-term study, could not be
confirmed in another controlled double-blind
study in elderly chronic schizophrenic patients.
After 12 months 93% in the amisulpride group and
96% in the haloperidol group demonstrated oro-
facial dyskinesias – which represented a small in-
crease compared to the base-line values for both
groups [47, 115]. The available evidence suggests
that clozapine does not cause TD at all; up-to-date
no clear case of TD that could be ascribed to the
sole use of clozapine has been reported. A one year
study concerning this issue could not find any ev-
idence that clozapine can cause TD [116]. How-
ever, the available data support the notion that pre-
existing TD can improve during treatment with
clozapine (for a review see [117]). This effect is not
the result of an active process but rather due to the
absence of any further noxious compounds [118].
It is also not protective since the re-exposure to
classical antipsychotics will again lead to an in-
crease of the TD rate [119].
Weight gain
In many patients treatment with antipsy-
chotics results in a substantial, often reversible
weight gain [120]. In some cases a weight gain of
up to 25 kg has been observed. The mechanisms
underlying this side effect are poorly understood.
Factors that are thought to play a role are sedation,
lack of movement, reduced satiety as well as a host
of endocrinological changes [120–122]. The an-
tagonism of central 5-HT2 receptors seems to play
an important role. It is believed that this blockade
results in an increased appetite and excessive food
intake. This may explain why particularly atypical
antipsychotics lead to substantial weight gain [123,
124]. Weight gain occurs over the whole dose
range, consistent with the observation that even
small doses of atypical antipsychotics result in an
almost total blockade of serotonergic receptors
[22, 23, 100]. After a treatment of 10 weeks the fol-
lowing average weight increases have to be ex-
pected: clozapine (4.45 kg), olanzapine (4.15 kg),
thioridazine (3.19 kg), risperidone (2.10 kg),
haloperidol (1.08 kg), fluphenazine (0.43 kg),
ziprasidone (0.04 kg), placebo (–0.74 kg) [123].
Treatment with quetiapine – not included in the
previously cited meta-analysis – seems to be asso-
ciated with significant weight gain in some, but not
all studies [124, 125]. The only exception seems to
be ziprasidone – an atypical antipsychotic demon-
strating presynaptic re-uptake inhibition of sero-
tonin and noradrenalin comparable to antidepres-
sants. Treatment with ziprasidone does not seem
to induce weight gain [123, 124]. Furthermore,
dyslipidaemias, particularly elevation of triglyc-
erides, have been observed during treatment with
various atypical antipsychotics [126]. It has to be
stressed that such increases may occur in the ab-
sence of concomitant weight gain.
Glucose regulation
Hyperglycaemia and type 2 diabetes mellitus
(DM) are more common in schizophrenic patients
than in the general population. Abnormalities in
glucose regulation have also been associated with
the use of antipsychotic medications, especially
with the use of atypical agents [127]. Though the
underlying mechanism of action is not fully un-
derstood and may vary amongst different com-
pounds there is evidence that clozapine and olan-
zapine induce insulin resistance leading to a patho-
logic glucose regulation [127, 128]. In general,
weight gain is a robust risk factor for type 2 DM.
In particular, being overweight at baseline, a posi-
tive personal or family history, and ethnicity (peo-
ple of African descent) have found to be risk fac-
tors for developing DM during treatment with an-
tipsychotics [127]. However, there is growing evi-
dence that some patients treated with atypical an-
tipsychotics may present with new onset DM or
even diabetic ketoacidosis (DKA) in the absence of
weight gain or any familial or individual risk fac-
tors [129]. DM or DKA have been reported re-
peatedly during treatment with clozapine and
olanzapine and in a few single cases during treat-
ment with risperidone and quetiapine [130–132].
For both clozapine and olanzapine the hyper-
glycemia resulted in at least one fatality. To our
knowledge no cases of DM or DKA have been re-
ported for amisulpride or ziprasidone. 
Prolactin
Prolactin, a polypeptide of the hypophyseal
gland, is tonically controlled by dopamine which
inhibits by way of the portal venous system the re-
lease of this hormone. The blockade of the
dopaminergic transmission results in an increase of
prolactin secretion. The clinical results are dys-
function of the menstrual cycle, loss of libido,
swelling of the mamillary glands as well as galac-
torrhea and possibly osteoporosis [133]. Due to 
the regionally unselective central blockade of
dopamine D2 receptors all conventional antipsy-
chotics can result in a prolactin increase. However,
atypical antipsychotics vary in this regard. Cloza-
pine, olanzapine, quetiapine, and ziprasidone re-
sult – in most cases – in a clinically insignificant or,
at most, transient increase of prolactin. Risperi-
done does not substantially differ from conven-
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tional antipsychotics in this regard. During treat-
ment with amisulpride an even higher increase of
prolactin has to be expected than during treatment
with classical antipsychotics [134–138].
QTc-prolongation
QTc-prolongations have been described for all
atypical antipsychotics. However, these seem to be
rare occurrences with the exception of ziprasidone
and sertindole which, for this reason, was sus-
pended in 1999. According to the manufacturers
specifications (as approved for Germany) ziprasi-
done causes a dose-dependent QTc-prolongation
with an increase of 30–60 msec in 12.3% of pa-
tients. Although the information by the manufac-
turer does not contain recommendations for elec-
trocardiograms (EKGs), it alerts clinicians to the
possibility of QTc-prolongation. Routine EKG
monitoring for ziprasidone is recommended by a
recent consensus meeting [139]. For other atypi-
cal antipsychotics EKG monitoring is not rou-
tinely indicated, but should be performed when
treatment with very high doses is planned or in the
presence of other risk factors (eg, co-medication
with possible interactions, hypokalaemia, hypo-
magnesaemia, cardio-vascular disease). 
Other side effects
Sedation: Treatment with clozapine and olan-
zapine may be associated with significant sedation,
whereas quetiapine and ziprasidone usually cause
rather mild and transitory somnolence. On the
other hand, risperidone and amisulpride can cause
agitation and insomnia.
Liver enzymes: All atypical antipsychotics can
lead to an increase of liver enzymes. In most cases
these increases are transient without any conse-
quences for treatment. A hepatitis proper occurs
very rarely.
Agranulocytosis: Treatment with clozapine is as-
sociated with an increased risk (less than 1%) of
agranulocytosis. For this reason monitoring of the
white blood cell count is mandatory. Myelosup-
pressive effects that manifest as neutropenias or
even agranulocytoses have been described for
olanzapine and risperidone as well. In a few cases
olanzapine prolonged neutropenias that initially
occurred during treatment with clozapine
[140–144].
Cholinergic system: Clozapine exerts strong an-
ticholinergic effects centrally and peripherally re-
sulting in problems with vision and constipation,
urinary problems and – in some cases – in frank
delirium. Olanzapine, quetiapine, and ziprasidone
also show anticholinergic side effects, albeit to a
lesser degree than observed during clozapine treat-
ment. Risperidone and amisulpride lack anti-
cholinergic effects. Medication with clozapine
often results in sialorrhea, believed to be mediated
by a direct effect on the parotid gland.
a-adrenolysis: Clozapine, risperidone, quetia-
pine, and – to a lesser degree – ziprasidone possess
a-adrenolytic effects resulting in orthostatic hy-
potension and possibly reflex tachycardia. For this
reason slow titration of these medications is rec-
ommended.
Sexual side effects: All atypical antipsychotics
may lead to the occurrence of sexual side effects.
They mainly include dysfunctions of the female
cycle and of the libido as well as disorders of erec-
tion and ejaculation. These effects are believed to
be mediated by drug-induced hyperprolactinemia
and peripheral anti-a-adrenergic effects. It is im-
portant to address these side effects openly and di-
rectly with patients since such complaints are
rarely volunteered. 
Seizures: Epileptic seizures can occur occa-
sionally during treatment with atypical antipsy-
chotics. An increased risk is seen particularly dur-
ing treatment with clozapine at higher doses
(above 500 mg).
Malignant neuroleptic syndrome (MNS): The oc-
currence of MNS has been described for all atyp-
ical antipsychotics, even for the recently intro-
duced ziprasidone [145]. However, the available
evidence indicates that this is a rare complication,
particularly in the case of clozapine. If treatment
after the occurrence of MNS or malignant catato-
nia is indicated clozapine should be the treatment
of choice since this atypical drug can be regarded
as extremely safe concerning MNS [146].
Myocarditis: Myocarditis is a rare, but often
fatal complication of clozapine treatment that usu-
ally occurs within the first few weeks of treatment
[147,148] (see also revised package insert). In pa-
tients presenting with unexplained fatigue, chest
pain, dyspnoea and other signs and symptoms of
heart failure myocarditis should be considered.
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Pharmacokinetic interactions
Most atypical antipsychotics are extensively
metabolised by one or several of the various isoen-
zymes of the hepatic cytochrome P450 (CYP) sys-
tem with no significant enzyme induction and no
or only moderate enzyme inhibition (eg, risperi-
done). Caution has to be exerted when combining
atypical antipsychotics with other pharmacologi-
cal agents that are known to lead to induction or
inhibition of liver enzymes and may thus be able
to change plasma levels of medications. 
Clozapine is a substrate of several CYP isoen-
zymes, namely CYP1A2, CYP3A4, and CYP2D6.
Both ciprofloxacin (CYP1A2 inhibitor) and eryth-
romycin (CYP3A4 inhibitor) when given together
with clozapine can cause increased plasma cloza-
pine levels and toxic symptoms such as ataxia,
dysarthria, disorientation, somnolence [149, 150].
Elevated plasma clozapine levels with or without
clinical signs of intoxication are to be expected
with concurrent administration of cimetidine (but
not ranitidine [151]), paroxetine, fluoxetine, and
caffeine. During treatment with fluvoxamine, a
known inhibitor of CYP1A2, up to 10-fold in-
creases of plasma clozapine levels have been ob-
served [152]. A strong increase of plasma cloza-
pine levels has been seen after the addition of
risperidone to clozapine treatment, but the under-
lying mechanism of interaction between the two
drugs remained unclear [153]. On the other hand,
compounds which induce the activity of CYP450
isoenzymes (eg, rifampicin, carbamazepine) may
lower the plasma clozapine levels and thus provoke
a psychotic relapse. Cigarette smoking is known to
induce CYP1A2 activity and smoking cessation has
been related to increased plasma clozapine levels
and toxic effects [154]. 
Risperidone is mainly oxidised by CYP2D6 and
is considered itself to be a weak inhibitor of the
CYP2D6 isoenzyme [153]. Co-medication with
CYP2D6 inhibitors such as fluoxetine, paroxetine,
perphenazine, thioridazine, and levomepromazine
can lead to an increase of plasma risperidone lev-
els, whereas carbamazepine has been linked to the
opposite effect. The occurrence of parkinsonian
symptoms after carbamazepine discontinuation
has been reported in two patients concurrently
treated with risperidone [155].
Olanzapine is mainly metabolised by the cy-
tochrome P450 isoenzyme CYP1A2. Therefore
increased plasma olanzapine levels are to be ex-
pected when CYP1A2 inhibiting compounds are
co-administred, eg, fluvoxamine and cipro-
floxacin. However, due to the large safety margin
of olanzapine, elevated plasma olanzapine levels
may lead to EPS, but rarely to other clinically rel-
evant manifestations. Both co-medication with
carbamazepine and cigarette smoking are able to
decrease plasma olanzapine levels. Indeed, Zullino
et al reported on a patient experiencing important
extrapyramidal symptoms after reducing his to-
bacco consumption [154].
Quetiapine is known to be a major substrate of
CYP3A4. Therefore, alterations of plasma quetia-
pine levels may occur when inhibitors (eg, keto-
conazole, erythromycin, grapefruit juice) or in-
ducers of the CYP3A4 isoenzyme (eg, phenytoin,
carbamazepine, hypericum) are given together
with quetiapine. In an open-label randomised trial
co-medication with thioridazine significantly in-
creased the clearance of quetiapine whereas
haloperidol and risperidone did not have any im-
portant effects on the pharmacokinetics of quetia-
pine [156].
Amisulpride is metabolised less extensively by
the hepatic cytochrome P450 system and its clear-
ance occurs mostly by renal excretion. To our
knowledge no important pharmacokinetic interac-
tions concerning the cytochrome P450 system
have been reported up to date and the compound
my be of special interest in patients with hepatic
complications due to other antipsychotics [157].
Ziprasidone is predominantly metabolised by
the CYP3A4 isoenzyme and is not expected to me-
diate drug interactions with other coadministred
CYP substrates. Hence, caution is to be exerted
when CYP3A4 inhibitors or inductors (see above)
are prescribed together with ziprasidone [158,
159]. Concurrent administration of carba-
mazepine has been reported to moderately lower
plasma ziprasidone levels [158, 159]. 
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Conclusions (see table 3)
In comparison with conventional antipsy-
chotics atypical antipsychotics show at least an
equal efficacy against positive symptoms. They
may exert more beneficial effects in the reduction
of global negative symptoms. The substantial ad-
vantage of atypical antipsychotics over classical
compounds is the greatly reduced occurrence of
acute extrapyramidal side effects and, during a pro-
longed treatment, a reduced incidence of TD
[160]. It has to be pointed out, however, that these
observations have been made in chronically ill pa-
tients and, in most cases, in comparison to rather
high doses of haloperidol. For these reasons these
differences may not hold true in comparison to all
classical antipsychotics or in clinically different sit-
uations (for instance first episode patients). For in-
stance, in 350 neuroleptic-naive patients treated
with low doses of haloperidol (3.7 mg/d) or risperi-
done (3.2 mg/d) the incidence and severity of EPS
was similar [161]. 
Atypical antipsychotics may be used in the
acute and long-term treatment of schizophrenia as
well as in all stages, ie, in first episode and chronic
patients. However, with the exception of risperi-
done, soon to be marketed in an injectable slow-
release formulation, none of the atypical antipsy-
chotics is available in depot form to date; thus in
many situations where compliance is crucial, clas-
sical antipsychotics in an injectable long-acting
form are still the treatment of choice. In antipsy-
chotic-naive first episode patients the lowest pos-
sible dose should be used since these patients ap-
pear to respond particularly well to antipsychotic
treatments and, at the same time, are very sensitive
to develop EPS [162, 163]. For instance, if seda-
tion of a patient is required it should not be
achieved by increasing the dose of the antipsy-
chotics, but by temporarily giving an additional
sedative medication such as a benzodiazepine. If
negative symptoms dominate the clinical picture
amisulpride in a dose of 50–300 mg/d is recom-
mended. A concurrently existing positive sympto-
matology is, however, not treated with this dose.
In case of a postpartal psychosis that requires an-
tipsychotic medication women who want to breast
feed their infants should not be treated with atyp-
ical antipsychotics because of the limited experi-
ence with these agents [164]. After weaning cloza-
pine, quetiapine, olanzapine, and ziprasidone
should be preferred since these substances rarely
induce a sustained increase of the prolactin level.
If sedative effects have to be avoided amisulpride
and risperidone are recommended. The occur-
rence of disabling or progressive tardive dyskine-
sias as well as the existence of documented treat-
ment-resistance are unequivocal indications for
clozapine. A previous non-response to olanzapine
is no contraindication to the use of clozapine [66].
It is always recommended to conduct changes of
medication in improved or remitted patients in an
overlapping fashion over days and weeks. Particu-
lar caution has to be exerted when stopping cloza-
pine. An abrupt cessation may be associated with
withdrawal symptoms, cholinergic rebounds, and,
more rarely, with a very rapid emergence of psy-
chotic symptoms (so-called rebound psychosis). In
addition, cases have been described in which the
superiority of clozapine was lost [165–167]. 
The advantages of a lower EPS liability with
regard to extrapyramidal side effects contrast with
some important untoward effects of atypical an-
tipsychotics. Foremost are metabolic disorders
and weight gain which have to be expected to var-
ious extent during the treatment with all atypical
antipsychotics except amisulpride and ziprasidone.
These side effects have to be taken seriously since
they may lead to further, particularly cardiovascu-
lar, morbidity. Less dangerous, but no less dis-
abling subjectively, are sexual side effects. How-
ever, there is evidence, particularly for clozapine,
that treatment with atypical antipsychotics is asso-
ciated with more patient satisfaction and may thus
lead to better compliance – a crucial factor in the
treatment of schizophrenia [55, 168].
Other important considerations for prescrib-
ing atypical antipsychotics are their rather high
prices. If these expenses are justified – for instance
by an improved long-term course of schizophrenia
– remains to be seen. It is clear, however, that atyp-
ical antipsychotics should not be used irrespective
of the clinical situation but tailored to the individ-
ual needs of each patient and under careful con-
sideration of the advantages and disadvantages.
Furthermore, psychopharmacological treatment
of patients with schizophrenia should always be
part of a sound treatment plan that includes psy-
chosocial as well as rehabilitative interventions.
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Risperidone Olanzapine Quetiapine Ziprasidone Amisulpride Clozapine
Positive symptoms +++ +++ +++ +++ +++ +++
Primary negative symptoms1 + + + ++ ++2 +
Treatment resistance + + 0 ? ? +++
Acute EPS +/++3 0/+3 0 0 0/+3 0
TD + + + + + 0
Weight gain +/++ ++/+++ ? 0 0 +++
Prolactin increase +/++ 0/+ 0/+ 0/+ +++ 0/+
Sedation 0/+ ++ +/++ ++ 0 +++
Agranulocytosis 0 0 0 0 0 +
Anticholinergic effects 0/+ + 0/+ 0/+ 0 +++
Orthostasis (a-adrenolytic) ++ 0 ++ + 0 +++
Sialorrhea 0 0 0 ++ 0 +++
Hyperglycaemia 0/+ ++ 0/+ 0 0 ++
* the frequencies in the table are relative, not absolute and only comparable within the same row
0 not or only very rarely present
+ rarely present, minimal effect
++ occasionally present, moderate effect
+++ often present, strong effect
1 effects on secondary negative symptoms may be greater and clinically significant
2 in doses of 50–300 mg/d 
3 dose dependent
? evidence not sufficient or contradictory
Table 3
Clinical characteris-
tics and side effects
of atypical antipsy-
chotics.*
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